Is this a buying opportunity?
Umbralisib is in Phase 3 trials in hematologic malignancies.
First FDA-approved treatment for primary haemophagocytic lymphohistiocytosis (HLH). (Image: Novimmune)
Company chart and information is provided by TradingView based on 15-minute-delayed data.
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
| Website: | www.tgtherapeutics.com |
| Email: | ir@tgtxinc.com |
| Main Phone: | +1 212 554-4484 |
| Address: | 2 Gansevoort Street |
| Address 2: | 9th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | US |
| Postal Code: | 10014 |
| Exchange: | NSC |
| CEO: | Michael S. Weiss |
| Employees: | 272 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Is this a buying opportunity?
Umbralisib is in Phase 3 trials in hematologic malignancies.
First FDA-approved treatment for primary haemophagocytic lymphohistiocytosis (HLH). (Image: Novimmune)
Data presented at ECTRIMS, the world's largest MS conference
Christmas comes but once a year, but a portfolio with huge returns is the gift that just keeps on giving. That’s why we’re taking the end of the year to look back at those investments
Stock in TG Therapeutics (TGTX) popped in Wednesday trading, seeing shares bounce 9.11%. Driving the gains appears to be the favorable deal secured by rival Infinity (INFI) with AbbVie (ABBV)
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Since their introduction over the past decade, Exchange Traded Funds (ETFs) have quickly established themselves as a standard and highly sought-after financial instrument for investors.ETFs are
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
